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Background: It has been proposed that COPD is an
independent predictor of cardiovascular disease (CVD).
Arterial stiffness has been shown to predict CVD and
aortic augmentation index (AIx) is an easily obtained
measure of arterial wave reflection – that can be used
as a surrogate measure of arterial stiffness.
Objective: To examine the association between COPD
and lung function (FEV1, FVC) in general, and arterial
stiffness measured by AIx in a cohort of the Danish
population.
Methods: This population-study is based on 6300
subjects from the Copenhagen City Heart Study where
869 met the diagnostic criteria for COPD according to
GOLD. We looked at the crude association between AIx
corrected for heart rate (AIx75) and COPD as well as the
severity of COPD stratified by gender. Using multivariate
linear regression we examined the association between
AIx75 and COPD (moderate to severe) adjusted for age,
age squared, height and weight, factors known to be
associated with AIx75. We also looked at the effect of
COPD on AIx75 in a model fully adjusted for
cardiovascular risk factors.
Results: The crude analysis showed that AIx75 was
significantly increased in subjects with COPD and that
AIx75 increased with increasing severity of COPD
according to GOLD. After adjusting for age, age2, height
and weight the effect of COPD was marginally
significant in men, but not in women. In the model fully
adjusted for CVD risk factors there was no effect of
COPD on AIx75. In men, there was a significant
association between FEV1 as a continuous variable and
AIx75 in the model fully adjusted for CVD risk factors;
however, this was equally strong for FVC and not seen in
women.
Conclusions: Our findings question the role of COPD as
an independent risk factor for arterial stiffness and thus
for cardiovascular disease.
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Recent reports have shown an association between
periodontitis and chronic obstructive pulmonary disease
(COPD). Our objective was to assess if COPD status
affects the subgingival microflora based on culture-
independent methods. Eighteen subjects were classified
into four different groups according to clinical perio-
dontal status and to the airway obstruction after lung
function testing. DNA from subgingival plaque samples
was extracted and the bacterial 16S rRNA genes were
PCR amplified, cloned, and sequenced to determine
species identity. From a total of 1,041 clones, 168
species or phylotypes were detected. Species of
Granulicatella and Streptococcus were associated with
a healthy periodontium in both COPD and non-COPD
subjects. In the healthy subgingival microflora of COPD
subjects, higher amounts of Actinomyces spp.,
Veillonella spp. and Campylobacter gracilis were
detected as compared to healthy controls. COPD status
was found to have little influence on the subgingival
microflora in periodontitis subjects. In conclusion, COPD
status does seem to influence the healthy, but not the
diseased subgingival microflora in periodontitis. These
findings indicate that there may be host factors
responsible for the increased susceptibility of COPD
subjects to periodontal disease. The periodontal pocket
of COPD subjects was not found to be a reservoir for
recognized pulmonary pathogens.
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Aims: Patients suffering from chronic obstructive
pulmonary disease with alveolar hypoxia can also have
diastolic dysfunction in the right and left ventricle (LV).
In an experimental model we have shown that the LV
diastolic dysfunction may be caused by altered
phosphorylation of the calcium handling protein
phospholamban at serine (Ser) 16 in the myocardium.
The mechanisms leading to changes in phosphorylation
of phospholamban are explored.
Methods: In mice exposed to 10% oxygen, phosphatases
and signaling molecules were measured in cardiac tissue
and serum. Cardiomyocytes isolated from mice were
exposed to hypoxia-induced cytokines for 24 hours.
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Results: Alveolar hypoxia led to a significantly higher
amount (124%) and activity (234%) of protein phospha-
tase (PP) 2A in membrane preparations from LV
compared to control. Serum levels of several cytokines
were assayed, and a pronounced increase in IL-18 was
observed. In isolated cardiomyocytes, treatment with
IL-18 increased the amount and activity of PP2A, and
reduced phosphorylation of phospholamban at Ser16 to
54% of control.
Conclusions: Our results indicate that the diastolic
dysfunction observed in alveolar hypoxia might be
caused by increased levels of interleukin-18 inducing an
increase in PP2A in the heart and thereby a reduction in
phosphorylation of phospholamban at Ser16.
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Low lung function is associated with increased risk for
cardiovascular disease (CVD). Atherosclerotic plaques in
the internal carotid artery (ICA) is a known risk factor
for stroke. The objective for this study was to examine
the prevalence of atherosclerotic plaques in the ICA in
subjects with COPD and to examine potential associa-
tions between the occurrence of atherosclerotic plaques
in the ICA and different lung function parameters.
The invited study population consisted of 450
subjects (41% men), aged 46-78 years, who comprised a
subset of a population based sample. A complete lung
function test including diffusing capacity of carbon
monoxide was performed. COPD was diagnosed in
subjects who had a ratio of FEV1/VC <0.7. Ultrasound
was used to screen the ICA bilaterally for plaques.
The prevalence of atherosclerotic plaques in the ICA
in the COPD group was 64%, in the non-COPD group 47%.
Most of the differences in lung function among subjects
with and without atherosclerotic plaques in the ICA
could not be seen after adjustments for different risk
factors for atherosclerosis. Interestingly though,
differences in residual volume and diffusing capacity of
carbon monoxide remained after such adjustments,
suggesting a possible association between lung
parenchymal changes and atherosclerotic plaques in the
ICA.
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A large part of the costs of chronic obstructive
pulmonary disease (COPD) are due to comorbidities (1).
Little is known concerning the costs related to co-
morbidities in COPD in the Scandinavian countries.
We present the baseline data of a 1-year prospective
survey of the health economic aspects of COPD in
Norway (EconCOPD) (2). 136 smokers without COPD
(controls) and 90 smokers with COPD stage 2+ (cases) (3)
were included from the general population in spring
2005, based on spirometry results in 2003-2004. In
addition we included 250 hospital patients with COPD
stage 2+ (patients). Participants reported comorbidities
and self-reported healthcare costs (drugs, visits to
healthcare providers, aid equipment, help with
activities of daily living and rehabilitation) the
preceding 3 months at baseline.
The mean FEV1 % predicted was 95.3%, 64.5% and
47.2% among controls, cases and patients respectively.
There were more men in all three groups of
participants, and more current smokers among the
patients. 50% of controls, 66% of cases and 74% of
patients reported comorbid conditions. Subjects with
comorbidities reported larger healthcare costs (p<0.05)
within all three groups of participants except within the
cases.
Future analyzes on the EconCOPD data will enable
calculation of costs generated by excess comorbidity in
COPD.
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